A prognostics company, Genetics Squared Inc had been organized originally around development of gene-based molecular assays for the prediction of cancer recurrence: molecular diagnostic tests especially well suited for clinical oncology though also applied in other areas of clinical and preclinical biomedical research, such as infectious disease, nephrology, and autoimmune disease, In January 2011, the firm announced name change to Everist Genomics conicident with launch its first prognostic gene-based laboratory testâOncoDefenderâ¢-CRCâintended to help guide treatment decisions following surgery for Stage I/II colon cancer and Stage I rectal cancer. In June 2013, the firm again renamed itself - this time to Everist Health Inc. with a shift towards development and commercialization of diagnostic and prognostic tests that help patients and their physicians to manage their personal health. With a worldwide presence now in many countries, product offerings include AngioDefender system, a non-invasive device to assess the presence of early-stage cardiovascular diseases and atherosclerosis; and a Vascular Age Calculator to determine the vascular age of the indivi